As BioMarin turns to commercialization of Roctavian, we will likely hear more about how warranties could help gene therapies overcome payer reimbursement hurdles.
BioMarin’s Next Roctavian Challenge Is How To Successfully Commercialize Its Gene Therapy: Warranties May Be An Option
